Targeting Apoptotic Pathways in Melanoma View Full Text


Ontology type: schema:Chapter     


Chapter Info

DATE

2011-11-13

AUTHORS

Peter Hersey , Xu Dong Zhang

ABSTRACT

Impairment of cell death is a key property of cancer cells. It follows that irrespective of the target of new therapies cell survival mechanisms will need to be overcome for the treatment to be effective. Considerable information is now available about the mechanisms responsible for cancer cell survival. These center largely on the Bcl-2 protein family and the inhibitor of apoptosis proteins. They are regulated by complex pathways that are often initiated by the oncogenic process. A number of new treatments that target the anti- and proapoptotic proteins are at various stages of development and evaluation. In addition, there is an ever-increasing number of agents that target signal pathways involved in regulation of these protein families and which may have potent apoptosis-inducing activities. Complex feedback mechanisms initiated by these treatments as well as the inherent variability of melanoma cells are obstacles that remain to be overcome. Nevertheless, they would appear to be an essential component of future treatment strategies against melanoma. More... »

PAGES

125-153

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/978-1-61779-407-0_9

DOI

http://dx.doi.org/10.1007/978-1-61779-407-0_9

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1014637856


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/06", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Biological Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/0601", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Biochemistry and Cell Biology", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1112", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Oncology and Carcinogenesis", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Oncology & Immunology Unit, University of Newcastle, Kolling Institute Univesity of Sydney, Room 443, David Maddison Clinical Sciences Building, Cnr King & Watt Streets, 2300, Newcastle, NSW, Australia", 
          "id": "http://www.grid.ac/institutes/grid.266842.c", 
          "name": [
            "Oncology & Immunology Unit, University of Newcastle, Kolling Institute Univesity of Sydney, Room 443, David Maddison Clinical Sciences Building, Cnr King & Watt Streets, 2300, Newcastle, NSW, Australia"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Hersey", 
        "givenName": "Peter", 
        "id": "sg:person.01073667716.42", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01073667716.42"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Oncology & Immunology Unit, University of Newcastle, Kolling Institute Univesity of Sydney, Room 443, David Maddison Clinical Sciences Building, Cnr King & Watt Streets, 2300, Newcastle, NSW, Australia", 
          "id": "http://www.grid.ac/institutes/grid.266842.c", 
          "name": [
            "Oncology & Immunology Unit, University of Newcastle, Kolling Institute Univesity of Sydney, Room 443, David Maddison Clinical Sciences Building, Cnr King & Watt Streets, 2300, Newcastle, NSW, Australia"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Zhang", 
        "givenName": "Xu Dong", 
        "id": "sg:person.01210116316.18", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01210116316.18"
        ], 
        "type": "Person"
      }
    ], 
    "datePublished": "2011-11-13", 
    "datePublishedReg": "2011-11-13", 
    "description": "Impairment of cell death is a key property of cancer cells. It follows that irrespective of the target of new therapies cell survival mechanisms will need to be overcome for the treatment to be effective. Considerable information is now available about the mechanisms responsible for cancer cell survival. These center largely on the Bcl-2 protein family and the inhibitor of apoptosis proteins. They are regulated by complex pathways that are often initiated by the oncogenic process. A number of new treatments that target the anti- and proapoptotic proteins are at various stages of development and evaluation. In addition, there is an ever-increasing number of agents that target signal pathways involved in regulation of these protein families and which may have potent apoptosis-inducing activities. Complex feedback mechanisms initiated by these treatments as well as the inherent variability of melanoma cells are obstacles that remain to be overcome. Nevertheless, they would appear to be an essential component of future treatment strategies against melanoma.", 
    "editor": [
      {
        "familyName": "Gajewski", 
        "givenName": "Thomas F.", 
        "type": "Person"
      }, 
      {
        "familyName": "Hodi", 
        "givenName": "F. Stephen", 
        "type": "Person"
      }
    ], 
    "genre": "chapter", 
    "id": "sg:pub.10.1007/978-1-61779-407-0_9", 
    "isAccessibleForFree": false, 
    "isPartOf": {
      "isbn": [
        "978-1-61779-406-3", 
        "978-1-61779-407-0"
      ], 
      "name": "Targeted Therapeutics in Melanoma", 
      "type": "Book"
    }, 
    "keywords": [
      "protein family", 
      "Bcl-2 protein family", 
      "potent apoptosis-inducing activity", 
      "cell survival mechanism", 
      "cancer cell survival", 
      "apoptosis-inducing activity", 
      "apoptosis protein", 
      "survival mechanism", 
      "proapoptotic proteins", 
      "apoptotic pathway", 
      "cell survival", 
      "cell death", 
      "oncogenic processes", 
      "complex pathways", 
      "complex feedback mechanisms", 
      "cancer cells", 
      "stages of development", 
      "melanoma cells", 
      "future treatment strategies", 
      "pathway", 
      "protein", 
      "essential component", 
      "treatment strategies", 
      "new treatments", 
      "cells", 
      "considerable information", 
      "family", 
      "feedback mechanism", 
      "mechanism", 
      "melanoma", 
      "treatment", 
      "regulation", 
      "inhibitors", 
      "target", 
      "impairment", 
      "death", 
      "survival", 
      "activity", 
      "number", 
      "inherent variability", 
      "stage", 
      "variability", 
      "agents", 
      "number of agents", 
      "development", 
      "components", 
      "center", 
      "evaluation", 
      "addition", 
      "process", 
      "strategies", 
      "key properties", 
      "information", 
      "properties", 
      "obstacles"
    ], 
    "name": "Targeting Apoptotic Pathways in Melanoma", 
    "pagination": "125-153", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1014637856"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/978-1-61779-407-0_9"
        ]
      }
    ], 
    "publisher": {
      "name": "Springer Nature", 
      "type": "Organisation"
    }, 
    "sameAs": [
      "https://doi.org/10.1007/978-1-61779-407-0_9", 
      "https://app.dimensions.ai/details/publication/pub.1014637856"
    ], 
    "sdDataset": "chapters", 
    "sdDatePublished": "2022-09-02T16:13", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20220902/entities/gbq_results/chapter/chapter_278.jsonl", 
    "type": "Chapter", 
    "url": "https://doi.org/10.1007/978-1-61779-407-0_9"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/978-1-61779-407-0_9'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/978-1-61779-407-0_9'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/978-1-61779-407-0_9'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/978-1-61779-407-0_9'


 

This table displays all metadata directly associated to this object as RDF triples.

134 TRIPLES      22 PREDICATES      81 URIs      72 LITERALS      7 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/978-1-61779-407-0_9 schema:about anzsrc-for:06
2 anzsrc-for:0601
3 anzsrc-for:11
4 anzsrc-for:1112
5 schema:author Nbd281c7882e74ae5b6079303a08798c6
6 schema:datePublished 2011-11-13
7 schema:datePublishedReg 2011-11-13
8 schema:description Impairment of cell death is a key property of cancer cells. It follows that irrespective of the target of new therapies cell survival mechanisms will need to be overcome for the treatment to be effective. Considerable information is now available about the mechanisms responsible for cancer cell survival. These center largely on the Bcl-2 protein family and the inhibitor of apoptosis proteins. They are regulated by complex pathways that are often initiated by the oncogenic process. A number of new treatments that target the anti- and proapoptotic proteins are at various stages of development and evaluation. In addition, there is an ever-increasing number of agents that target signal pathways involved in regulation of these protein families and which may have potent apoptosis-inducing activities. Complex feedback mechanisms initiated by these treatments as well as the inherent variability of melanoma cells are obstacles that remain to be overcome. Nevertheless, they would appear to be an essential component of future treatment strategies against melanoma.
9 schema:editor Nbed59bb7126643a681c9f463aee3672c
10 schema:genre chapter
11 schema:isAccessibleForFree false
12 schema:isPartOf N9e97a5602aa54702838dfef24f43b40c
13 schema:keywords Bcl-2 protein family
14 activity
15 addition
16 agents
17 apoptosis protein
18 apoptosis-inducing activity
19 apoptotic pathway
20 cancer cell survival
21 cancer cells
22 cell death
23 cell survival
24 cell survival mechanism
25 cells
26 center
27 complex feedback mechanisms
28 complex pathways
29 components
30 considerable information
31 death
32 development
33 essential component
34 evaluation
35 family
36 feedback mechanism
37 future treatment strategies
38 impairment
39 information
40 inherent variability
41 inhibitors
42 key properties
43 mechanism
44 melanoma
45 melanoma cells
46 new treatments
47 number
48 number of agents
49 obstacles
50 oncogenic processes
51 pathway
52 potent apoptosis-inducing activity
53 proapoptotic proteins
54 process
55 properties
56 protein
57 protein family
58 regulation
59 stage
60 stages of development
61 strategies
62 survival
63 survival mechanism
64 target
65 treatment
66 treatment strategies
67 variability
68 schema:name Targeting Apoptotic Pathways in Melanoma
69 schema:pagination 125-153
70 schema:productId N8e1164c7736240e18462c3b9d1b29805
71 Na39ad6780c1c45a79d4c2e9879d8da8f
72 schema:publisher N3bf14952a67a40eda6b809c4cf7206a0
73 schema:sameAs https://app.dimensions.ai/details/publication/pub.1014637856
74 https://doi.org/10.1007/978-1-61779-407-0_9
75 schema:sdDatePublished 2022-09-02T16:13
76 schema:sdLicense https://scigraph.springernature.com/explorer/license/
77 schema:sdPublisher N3f02a0ad3cbf45019a8b8a2ce7c258a7
78 schema:url https://doi.org/10.1007/978-1-61779-407-0_9
79 sgo:license sg:explorer/license/
80 sgo:sdDataset chapters
81 rdf:type schema:Chapter
82 N1adde25fd6464e358f7f053f01fc0a88 rdf:first Ne9e9922cd8b04b6d890eabaedb5624d0
83 rdf:rest rdf:nil
84 N3bf14952a67a40eda6b809c4cf7206a0 schema:name Springer Nature
85 rdf:type schema:Organisation
86 N3f02a0ad3cbf45019a8b8a2ce7c258a7 schema:name Springer Nature - SN SciGraph project
87 rdf:type schema:Organization
88 N51dc2bf3816048ffb8748a74c07f29f9 rdf:first sg:person.01210116316.18
89 rdf:rest rdf:nil
90 N8e1164c7736240e18462c3b9d1b29805 schema:name dimensions_id
91 schema:value pub.1014637856
92 rdf:type schema:PropertyValue
93 N9e97a5602aa54702838dfef24f43b40c schema:isbn 978-1-61779-406-3
94 978-1-61779-407-0
95 schema:name Targeted Therapeutics in Melanoma
96 rdf:type schema:Book
97 Na39ad6780c1c45a79d4c2e9879d8da8f schema:name doi
98 schema:value 10.1007/978-1-61779-407-0_9
99 rdf:type schema:PropertyValue
100 Nbd281c7882e74ae5b6079303a08798c6 rdf:first sg:person.01073667716.42
101 rdf:rest N51dc2bf3816048ffb8748a74c07f29f9
102 Nbed59bb7126643a681c9f463aee3672c rdf:first Nfc8186cbc9c44817bde67b3c7095863d
103 rdf:rest N1adde25fd6464e358f7f053f01fc0a88
104 Ne9e9922cd8b04b6d890eabaedb5624d0 schema:familyName Hodi
105 schema:givenName F. Stephen
106 rdf:type schema:Person
107 Nfc8186cbc9c44817bde67b3c7095863d schema:familyName Gajewski
108 schema:givenName Thomas F.
109 rdf:type schema:Person
110 anzsrc-for:06 schema:inDefinedTermSet anzsrc-for:
111 schema:name Biological Sciences
112 rdf:type schema:DefinedTerm
113 anzsrc-for:0601 schema:inDefinedTermSet anzsrc-for:
114 schema:name Biochemistry and Cell Biology
115 rdf:type schema:DefinedTerm
116 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
117 schema:name Medical and Health Sciences
118 rdf:type schema:DefinedTerm
119 anzsrc-for:1112 schema:inDefinedTermSet anzsrc-for:
120 schema:name Oncology and Carcinogenesis
121 rdf:type schema:DefinedTerm
122 sg:person.01073667716.42 schema:affiliation grid-institutes:grid.266842.c
123 schema:familyName Hersey
124 schema:givenName Peter
125 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01073667716.42
126 rdf:type schema:Person
127 sg:person.01210116316.18 schema:affiliation grid-institutes:grid.266842.c
128 schema:familyName Zhang
129 schema:givenName Xu Dong
130 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01210116316.18
131 rdf:type schema:Person
132 grid-institutes:grid.266842.c schema:alternateName Oncology & Immunology Unit, University of Newcastle, Kolling Institute Univesity of Sydney, Room 443, David Maddison Clinical Sciences Building, Cnr King & Watt Streets, 2300, Newcastle, NSW, Australia
133 schema:name Oncology & Immunology Unit, University of Newcastle, Kolling Institute Univesity of Sydney, Room 443, David Maddison Clinical Sciences Building, Cnr King & Watt Streets, 2300, Newcastle, NSW, Australia
134 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...